![]() |
市場調查報告書
商品編碼
1656901
預填充式注射器的全球市場:洞察,競爭情形,市場預測:2032年Prefilled Syringes - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
預計 2024 年預充式註射器市場規模將達到 12,490,790,000 美元。預計預測期內(2025-2032 年),市場複合年增長率為 10.73%,到 2032 年將達到 279.9335 億美元。由於慢性病的增加、生物製劑和生物相似藥的使用增加以及自我給藥的採用,全球預充式註射器市場正在成長。糖尿病和類風濕性關節炎等慢性疾病需要持續注射治療,預充式註射器為患者提供了安全、方便的治療方式。生物製劑和生物相似藥用於治療癌症和自體免疫疾病等複雜疾病,進一步推動了對易於使用的注射系統的需求。此外,在家中自行給藥的轉變提供了額外的便利,從而增加了對預充式註射器的整體需求。綜合起來,這些因素使得預充式註射器在 2025 年至 2032 年的預測期內將呈現強勁的成長軌跡。
根據世界心臟組織(WHO)提供的最新數據(2023年),全球約有5.28億人患有骨關節炎。
此外,根據健康指標與評估研究所 (2023) 提供的最新數據,預計到 2050 年將有約 10 億人患有骨關節炎,其中膝蓋和臀部是最常見的患處。具體而言,膝關節骨關節炎預計增加74.9%,腕關節骨關節炎預計將增加48.6%,髖關節骨關節炎預計增加78.6%,肘部和肩部等其他部位骨關節炎預計增加95.1%。
患有骨關節炎的患者通常需要注射玻尿酸或皮質類固醇來緩解疼痛並改善關節活動性。預充式註射器為在診所和家中進行這些治療提供了一種方便且無菌的方式,從而促進了全球預充式註射器市場的發展。例如,由賽諾菲旗下子公司 Genzyme Corporation 生產的 Synvisc-One® 是一種預充式註射器,有助於潤滑和緩衝膝關節,緩解骨關節炎疼痛長達六個月。
此外,世界衛生組織 (WHO) (2023) 的最新數據報告稱,全球有超過 180 萬人患有多發性硬化症。多發性硬化症導致免疫系統錯誤地攻擊大腦和脊髓,影響許多方面的功能,包括認知、情緒、運動、感覺和視覺。預充式註射器對於治療這種疾病至關重要,因為它們提供了一種即用型、準確且易於使用的輸送系統,可簡化給藥、減少用藥錯誤並提高患者對治療方案的依從性。例如,AVONEX 是一種每週一次的複發性多發性硬化症治療藥物,採用 30mcg 肌肉注射預充式自註射器形式。
此外,單株抗體、生長因子和疫苗等生物製劑對於治療癌症和自體免疫疾病等慢性疾病至關重要。預充式註射器透過注射給藥,提供了一種方便且精確的給藥方法。此外,生物相似藥和生物相似藥的興起進一步推動了對預充式註射器的需求,提供了更便宜的治療選擇。
本報告提供全球預填充式注射器市場相關調查,提供市場概要,以及各產品類型,不同材料,各類型,各流通管道,各地區趨勢,及加入此市場的主要企業簡介等資訊。
Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, increase impact of biologics and biosimilar on prefilled syringes, increase adoption of self-administration across the globe.
The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032. The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.
Prefilled Syringes Market Dynamics:
According to the recent data provided by the World Heart Organization (2023), about 528 million people globally were living with osteoarthritis.
Additionally, according to the recent data provided by the Institute for Health Metrics and Evaluation (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%.
Patients with osteoarthritis often need hyaluronic acid or corticosteroid injections for pain relief and joint mobility. Prefilled syringes provide a convenient and sterile method for administering these treatments in clinical and home settings, thus boosting the global prefilled syringe market. For example, Synvisc-One(R) manufactured by Genzyme Corporation, which is a subsidiary of Sanofi is a prefilled syringe that helps lubricate and cushion the knee joint, offering relief from osteoarthritis pain for up to six months.
Additionally, as per recent data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide were affected by multiple sclerosis. Multiple sclerosis impacted various functions, including cognitive, emotional, motor, sensory, and visual abilities, as the immune system mistakenly attacked the brain and spinal cord. Prefilled syringes were crucial for managing the condition, as they simplified dosing, reduced medication errors, and enhanced patient adherence to treatment regimens by offering a ready-to-use, accurate, and user-friendly delivery system. For instance, AVONEX is a once-weekly treatment for relapsing multiple sclerosis, provided as a 30 mcg intramuscular prefilled self-syringe.
Moreover, Biologics, including monoclonal antibodies, growth factors, and vaccines, are crucial for treating chronic conditions like cancer and autoimmune diseases. Administered via injection, prefilled syringes offer a convenient and accurate delivery method. Additionally, the rise of biosimilar generic versions of biologics has further propelled the demand for prefilled syringes, providing a more affordable treatment option.
For instance, in July 2024, Sandoz Group AG, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar Pyzchiva(R)* (ustekinumab-ttwe) in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, as well as a 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.
Thus, the factors mentioned above are expected to boost the overall market of prefilled syringes across the globe during the forecast period from 2025 to 2032.
However, increasing product recalls and failures due to safety issues and the availability of alternative products may hinder the future market of prefilled syringes across the globe during the forecasted period.
Prefilled Syringes Market Segment Analysis:
Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
The staked needle system category in the prefilled syringes market is estimated to dominate the market with a market share of 68.37% in 2024. The adoption of staked needle systems is significantly boosting the overall market of prefilled syringes by addressing key challenges in drug delivery and enhancing the usability, safety, and efficiency of injectable therapies. A staked needle system integrates the needle directly into the syringe barrel, eliminating the need for additional assembly, such as attaching a separate needle. This design simplifies the injection process, reduces preparation time, and minimizes the risk of needle-related complications, such as detachment or improper attachment, making it highly preferred in both clinical and self-administration settings.
One of the major drivers of the staked needle system's impact is its contribution to patient safety. The fixed-needle design reduces the risk of needle-stick injuries, which is a critical concern for healthcare professionals, especially in high-pressure environments like hospitals and emergency care. Additionally, the reduced dead space in staked needle systems ensures precise dosing and minimizes medication waste, which is particularly advantageous for high-cost biologics, vaccines, and specialty drugs. This attribute makes staked needle systems an ideal choice for administering small-volume, high-potency medications, aligning with the growing demand for precision medicine. The integration of staked needle systems into advanced prefilled syringes, such as autoinjectors and pen injectors, further boosts their appeal in the rapidly growing self-injection device market.
Pharmaceutical companies are increasingly adopting staked needle systems for their prefilled syringes due to their compatibility with a wide range of drugs, including biologics and biosimilars, which are gaining traction globally. The design ensures the sterility and integrity of the drug product, reducing the likelihood of contamination or degradation. Furthermore, staked needle systems are well-suited for high-speed, automated manufacturing processes, enabling efficient large-scale production while maintaining consistent quality, which aligns with the rising demand for prefilled syringes worldwide.
Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of prefilled syringes across the globe.
North America is expected to dominate the overall prefilled syringes market:
Among all regions, North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.
According to data provided by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 53.2 million people (21.2%), had been diagnosed with arthritis and rheumatoid arthritis in the United States, between 2019 to 2021.
Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, it was stated that around 38.4 million, accounting for 11.6% of the US population was suffering from diabetes, in 2021. Chronic diseases like diabetes and rheumatoid arthritis require continuous treatment over the long term. Patients need regular injections to manage their conditions, often for the rest of their lives. Prefilled syringes make these daily treatments easier, and more accurate, and allow easy self-administration of medications at home.
Furthermore, the well-established patient care system along with high awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the United States prefilled syringes market growth.
Moreover, the increasing use of prefilled syringes highlights the rapid adoption of technologically advanced solutions, which is expected to drive market growth. For instance, in March 2024, Mallinckrodt plc. announced that the U.S. FDA approved the Acthar(R) Gel (repository corticotropin injection) Single-Dose SelfJect(TM) Injector, a new delivery device for Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. The SelfJect was designed to allow patients greater control over their medication administration.
Thus, the above-mentioned factors are expected to escalate the market of prefilled syringes in the region.
Prefilled Syringes Market Key Players:
Some of the key market players operating in the Prefilled Syringes market include BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.
Recent Developmental Activities in the Prefilled Syringes Market:
Key Takeaways From the Prefilled Syringes Market Report Study
Target Audience Who Can be Benefited From This Prefilled Syringes Market Report Study
Frequently Asked Questions for the Prefilled Syringes Market: